drugset / Trial / NCT01486771

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771

Phase 4 Unknown 30 enrolled Valley Retina Institute Pfizer · collab
RandomizedFactorialOpen-labelTreatment

Summary

Intravitreal injections of pegaptanib will induce the regression of Proliferative Diabetic Retinopathy (PDR) and reduce the need for retinal photocoagulation.

Timeline

Start
2007-11
Primary completion
2013-08
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg Intravitreal